Safety and survival with GVAX pancreas prime and Listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer

Journal of Clinical Oncology

Volumn 33, Issue 12, 2015, Pages 1325-1333

  Le, Dung T ^a   Wang Gillam, Andrea ^c   Picozzi, Vincent ^d   Greten, Tim F ^b   Crocenzi, Todd ^e   Springett, Gregory ^f   Morse, Michael ^g   Zeh, Herbert ^h   Cohen, Deirdre ⁱ   Fine, Robert L ^j   Onners, Beth ^a   Uram, Jennifer N ^a   Laheru, Daniel A ^a   Lutz, Eric R ^a   Solt, Sara ^a   Murphy, Aimee Luck ^k   Skoble, Justin ^k   Lemmens, Ed ^k   Grous, John ^k   Dubensky, Thomas ^k   Brockstedt, Dirk G ^a   Jaffee, Elizabeth M ^a   more..

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c USA   (United States)

^d VIRGINIA MASON MEDICAL CENTER   (United States)

^e PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^j NewYork Presbyterian Hospital   (United States)

^k Aduro BioTech Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANCER VACCINE; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; LIVE ATTENUATED LISTERIA MONOCYTOGENES EXPRESSING MESOTHELIN; LIVER ENZYME; UNCLASSIFIED DRUG; ALKYLATING AGENT; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; GVAX VACCINE; MESOTHELIN;

ABDOMINAL PAIN; ADAPTIVE IMMUNITY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHILL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; IMMUNE RESPONSE; INJECTION SITE ERYTHEMA; INJECTION SITE EXFOLIATION; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INNATE IMMUNITY; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; BIOSYNTHESIS; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; IMMUNOLOGY; LISTERIA MONOCYTOGENES; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; SURVIVAL RATE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER VACCINES; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; FEMALE; GPI-LINKED PROTEINS; HUMANS; LISTERIA MONOCYTOGENES; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL RATE; T-LYMPHOCYTES, REGULATORY;

EID: 84929431322     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.4244     Document Type: Article

References (15)

1. Kantoff PW, Higano CS, Shore ND, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411-422, 2010
2. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
3. Topalian SL, Hodi FS, Brahmer JR, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454, 2012
4. Le DT, Lutz E, Uram JN, et al: Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother 36:382-389, 2013
5. Lutz E, Yeo CJ, Lillemoe KD, et al: A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation. Ann Surg 253:328-335, 2011
6. Beatty GL, Chiorean EG, Fishman MP, et al: CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612-1616, 2011
7. Laheru D, Lutz E, Burke J, et al: Allogeneic granulocyte macrophage colony-stimulating factorsecreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation. Clin Cancer Res 14:1455-1463, 2008
8. Thomas AM, Santarsiero LM, Lutz ER, et al: Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigenpresenting cells in vaccinated pancreatic cancer patients. J Exp Med 200:297-306, 2004
9. Brockstedt DG, Giedlin MA, Leong ML, et al: Listeria-based cancer vaccines that segregate immunogenicity from toxicity. Proc Natl Acad Sci U S A 101:13832-13837, 2004
10. Le DT, Brockstedt DG, Nir-Paz R, et al: A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: Phase I studies of safety and immune induction. Clin Cancer Res 18:858-868, 2012
11. Hwang IK, Shih WJ, De Cani JS: Group sequential designs using a family of type I error probability spending functions. Stat Med 9:1439-1445, 1990
12. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nabpaclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
13. Stein WD, Gulley JL, Schlom J, et al: Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 17:907-917, 2011
14. Sanda MG, Smith DC, Charles LG, et al: Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 53:260-266, 1999
15. Kantoff PW, Schuetz TJ, Blumenstein BA, et al: Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099-1105, 2010